A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Issue 37 (4th September 2018)

• Record Type: Journal Article
• Authors: Bhatt, Nikunj B.; Pandya, Darpan N.; Rideout-Danner, Stephanie; Gage, Howard D.; Marini, Frank C.; Wadas, Thaddeus J.
• Is Part Of: Dalton transactions. Volume 47:Issue 37(2018)
• Page Start: 13214
• Page End: 13221
• Publication Date: 2018-09-04
• Subjects: Chemistry, Inorganic -- Periodicals; Chemistry, Physical and theoretical -- Periodicals; Chemistry, Inorganic -- Periodicals; 546.05
• DOI: 10.1039/c8dt01841c
• Languages: English
• ISSNs: 1477-9226

Abstract

Abstract : Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. A comprehensively revised protocol for the production, quality control and long-term storage of 89 Zr-immuno-PET radiopharmaceuticals. Abstract : Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. This report describes a revised strategy that reduces preparation time while increasing the specific activity of clinically relevant immuno-PET agents. Additionally, it demonstrates that n -acetyl-l -cysteine acts as a superior radioprotective agent that improves long-term stability without compromising antigen affinity in vivo .